BARRY SPRINGER, PH.D.
HEAD OF EMERGING SCIENCES
SCIENTIFIC STRATEGY & OPERATIONS
Barry Springer, Ph.D., is Vice President and Head of Emerging Sciences, Scientific Strategy & Operations for Janssen BioTherapeutics (JBIO) within Janssen Research & Development.
Barry is responsible for identifying and evaluating external science and technologies of strategic interest to the JBIO and Discovery, Product Development & Supply (DPDS) organizations within Janssen Research & Development (JRD). He also leads the JRD cross function Integrated Technology Strategy that identifies and funds new innovative technologies of high strategic value. Barry and his teams partner with entrepreneurs worldwide and with internal colleagues in the JRD Therapeutic Areas and the Johnson & Johnson (J&J) Innovation teams (Innovation Centers, JLABS, JJDC and Janssen Business Development) to access the very best science, wherever it exists. Barry is also responsible for scientific operations across JBIO. He is based in Spring House, PA.
Barry’s professional leadership experience spans both large pharma and small biotech. He is accomplished in small molecule and biologics drug discovery and development as well as the invention and implementation of innovative technologies for both small and large molecules. Barry began his professional career at DuPont Merck and moved to 3-Dimensional Pharmaceuticals (3DP) as a founding member of the technology-based biotech company. During his tenure there, he invented and established a number of innovative technology platforms and led drug discovery efforts. Barry was also a key member of 3DP’s business development initiatives, one of which led to the acquisition of 3DP by J&J. Following the acquisition, Barry was named Vice President of Enabling Technologies for Johnson & Johnson Pharmaceutical Research & Development, Spring House Research and Early Development (RED) unit with global responsibilities. During that time, he established, built and led technology platform efforts. He was responsible for lead discovery, managing the new target portfolio and was a member of the RED leadership team that successfully achieved proof of concept for two therapies currently on the market, INVOKANA® and VIBERZI®.
Since 2011, Barry has led the external innovation efforts for biologics, which includes large molecule due diligence and in-licensing and implementation of technology platforms for biologics discovery and development such as the Genmab and Zymeworks multi-specific antibody platforms.
Barry has more than 40 peer reviewed publications and 40+ issued patents. He earned a Ph.D. in Biochemistry from the University of Illinois and completed postdoctoral training as a Helen Hay Whitney Fellow at U.C. Berkeley.